<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075241</url>
  </required_header>
  <id_info>
    <org_study_id>ZOLP-001</org_study_id>
    <nct_id>NCT03075241</nct_id>
  </id_info>
  <brief_title>Z-Drugs for Sleep Disorders in Alzheimer's Disease</brief_title>
  <official_title>Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brasilia University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brasilia University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Zolpidem and Zoplicone are efective in the
      treatment of sleep disorders in Alzheimer's disease (AD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleep disorders (SD) affects 35 to 50 percent of patients with AD. These disorders often make
      caring for patients at home very difficult. Zolpidem and Zoplicone are prescribed drugs for
      sleep disorder in AD patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nighttime Total Sleep Time</measure>
    <time_frame>Baseline, 14 days follow-up</time_frame>
    <description>Mean Total Sleep Time (in minutes) during the 12h nocturnal period (8:00pm-8:00am) after 2 weeks under treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daytime Total Sleep Time</measure>
    <time_frame>Baseline, 14 days follow-up</time_frame>
    <description>Daytime Total Sleep Time (in minutes) during the 12h daytime period (8:00am-8:00pm) after 2 weeks under treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of daytime to nighttime sleep</measure>
    <time_frame>Baseline, 14 days follow-up</time_frame>
    <description>Daytime Total Sleep Time / Nighttime Total Sleep Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nighttime Wake after Sleep Onset</measure>
    <time_frame>Baseline, 14 days follow-up</time_frame>
    <description>Nighttime Wake after Sleep Onset (in minutes) during the 12h nocturnal period (8:00pm-8:00am) after 2 weeks under treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of sleep time at nighttime</measure>
    <time_frame>Baseline, 14 days follow-up</time_frame>
    <description>Proportion of sleep time (%) during the 12h nocturnal period (8:00pm-8:00am) after 2 weeks under treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with gain of at least 30 minutes in Total Sleep Time</measure>
    <time_frame>Baseline, 14 days follow-up</time_frame>
    <description>Proportion of patients with gain of at least 30 minutes in Total Sleep Time after 2 weeks under treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between sleep efficiency between the two treatments.</measure>
    <time_frame>Baseline, 14 days follow-up</time_frame>
    <description>Analyze possible differences between sleep efficiency between the two treatments after 2 weeks under treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nighttime Number of Awakenings</measure>
    <time_frame>Baseline, 14 days follow-up</time_frame>
    <description>Change in scores of nighttime number of awakenings from baseline to intervention weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sleep</condition>
  <condition>Sleep Disorders</condition>
  <condition>Insomnia</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Zolpidem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study group will receive zolpidem 10mg capsules, 10pm (before bedtime) for 14 nights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoplicone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study group will receive zoplicone 7.5mg capsules, 10pm (before bedtime) for 14 nights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study group will receive inactive or inert capsules, which will be used as a comparator, 10pm (before bedtime) for 14 nights</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights</description>
    <arm_group_label>Zolpidem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoplicone</intervention_name>
    <description>Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights</description>
    <arm_group_label>Zoplicone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive or inert pill which will be used as a comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  55 years of age or older

          -  Diagnosis of probable Alzheimer's disease (AD) by National Institute of Neurological
             and Communicative Disorders and Stroke / the Alzheimer's Disease and Related Disorders
             Association Criteria

          -  Hachinski Ischemia Scale less than 5

          -  Mini-Mental State Examination score of 0 to 26

          -  Actigraph evidence of a mean time immobile of less than 7 hours per night based on at
             least 7 nights of complete actigraph data collected over a single week

          -  Four-week history of sleep disorder behaviors, occurring at least once weekly, as
             reported by the caregiver using the Neuropsychiatric Inventory (NPI) Nighttime
             Behavior scale

          -  Sleep disturbance observed was not present before the diagnosis of AD

          -  Other co-morbidities, especially delirium, depression, chronic pain and medication use
             may be present, but do not cooperate in the primary symptoms

          -  Computed tomography or magnetic resonance imaging since the onset of memory problems
             showing no more than 1 lacunar infract in a nonstrategic area and no clinical events
             suggestive of stroke or other intracranial disease or normal

          -  Stable medications for 4 weeks prior to the screening visit

          -  Having a mobile upper extremity to which to attach an actigraph

          -  Residing with a responsible spouse, family member, or professional caregiver who is
             present during the night and would agree to assume the role of the principle caregiver
             for the 3-week protocol

          -  Ability to ingest oral medication and participate in all scheduled evaluations

        Exclusion Criteria:

          -  Sleep disturbance associated with an acute illness, delirium or psychiatric disease

          -  Clinically significant movement disorder, such as akinesia, that would affect
             actigraphic differentiation of sleep and wakefulness

          -  Severe agitation

          -  Unstable medical condition

          -  Discontinuation of psychotropic or sleep medication within 2 weeks of the screening
             visit

          -  Patient unwilling to maintain caffeine abstinence after 2:00pm for the duration of the
             protocol

          -  Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and
             only 1 alcoholic drink after 6:00pm for the duration of the protocolo

          -  Prior use of zolpidem/zoplicone for the treatment os sleep disturbances

          -  Caregiver deemed to be unreliable to supervise the wearing of the actigraph, to
             administer study capsules at the proper time, to maintain the sleep diary, or to bring
             the patient to the scheduled visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciana L. Louzada, MD, MsC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brasilia University - Brasilia's University Hospital - Geriatric Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fl√°vio Vieira, MD, MsC</last_name>
    <phone>55 61 996304041</phone>
    <email>flaviovum@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Einstein F. Camargos, MD, MsC</last_name>
    <phone>55 61 99798345</phone>
    <email>einsteinfc@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Geriatric Medical Centre</name>
      <address>
        <city>Brasilia</city>
        <state>Distrito Federal</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana L Louzada, MD, MsC</last_name>
      <phone>55 61 991197587</phone>
      <email>lucianaelouzada@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2017</study_first_submitted>
  <study_first_submitted_qc>March 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brasilia University Hospital</investigator_affiliation>
    <investigator_full_name>Einstein Francisco de Camargos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Sleep Disturbances</keyword>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Z-Drugs</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

